Clinical trials: Vasospasm, Intracranial
Cerebral Vasospasm, Aneurysmal Subarachnoid Hemorrhage (aSAH)
Registry on NeVa VS for CerebraL VAsospasm ManagemenT in Post SAH PatiEnts
A multi-center, observational registry study intended to assess the HDE-approved NeVa VS cerebral artery dilation device in patients with symptomatic cerebral vasospasm caused by aneurysmal subarachnoid hemorrhage (aSAH)
- Trial name
- DILATE (NCT06893588)
- Testing
- NEVA VS
- Where
- 16 sites in United States
- Volunteers
- 200 people
- Sponsor
- Vesalio
Cerebral Vasospasm
Non-Significant Risk Study Comparing the Nautilus NeuroWaveTM to Transcranial Doppler as an Aid to Diagnosing Vasospasm
The purpose of the study is to determine the sensitivity, specificity and predictive values of the Jan Medical NeuroWave System in detecting moderate and severe vasospasm in comparison to Trans Cranial Doppler(TCD).
- Trial name
- NCT01595802
- Testing
- Nautilus NeuroWave, Transcranial Doppler (TCD)
- Where
- United States
- Volunteers
- 92 people
- Sponsor
- Jan Medical, Inc.
Cerebral Vasospasm
Vesalio NeVa VS for Symptomatic Cerebral Vasospasm Following aSAH (The VITAL Study)
The objective of the study is to assess the safety and probable benefit of the Neva VS device in patients presenting with symptomatic cerebral vasospasm despite maximal medical management following aSAH.
- Trial name
- NCT03611790
- Testing
- NeVa VS
- Where
- 10 sites in United States
- Volunteers
- 30 people
- Sponsor
- Vesalio
Aneurysmal Subarachnoid Hemorrhage
Evaluation of the Efficacy and Safety of Clazosentan in Reversing Cerebral Vasospasm in Adult Subjects With Aneurysmal Subarachnoid Hemorrhage
The purpose of this study is to evaluate the safety and potential therapeutic benefit of use of clazosentan in reversing cerebral vasospasm (a narrowing of blood vessels in the brain due to the presence of blood in the space…
- Trial name
- REVERSE (NCT02560532)
- Testing
- Clazosentan
- Where
- 11 sites in Finland, France and 1 more
- Volunteers
- 25 people
- Sponsor
- Idorsia Pharmaceuticals Ltd.
Aneurysmal Subarachnoid Hemorrhage
Clinical Research Study With Clazosentan to Evaluate Its Effects on Preventing Complications Due to the Narrowing of the Blood Vessels (Vasospasm) in the Brain, Caused by Bleeding Onto the Surface of the Brain
This study will evaluate if clazosentan (on top of normal routine medical care) can reduce the risk of developing complications related to cerebral vasospasm and permanent brain damage as compared to normal routine medical care…
- Trial name
- REACT (NCT03585270)
- Testing
- Clazosentan
- Where
- 80 sites in United States, Austria and 13 more
- Volunteers
- 409 people
- Sponsor
- Idorsia Pharmaceuticals Ltd.
Brain Injuries, Subarachnoid Hemorrhage
An Evaluation of a Non-invasive Brain Monitor
HS-1000 device, a proprietary new non-invasive brain monitor, is expected to safely and accurately monitor physiological signs of the brain with minimal discomfort to patients, providing information about normal or abnormal…
- Conditions
- Brain Injuries, Subarachnoid Hemorrhage, Vasospasm, Intracranial, Hydrocephalus
- Trial name
- NCT02775136
- Testing
- HS-1000 recording
- Where
- 4 sites in Germany
- Volunteers
- 160 people
- Sponsor
- HeadSense Medical
Subarachnoid Hemorrhage
Safety and Pharmacokinetic Evaluation of Nitrite for Prevention of Cerebral Vasospasm
The purpose of the study is to examine the safety of a 14 day infusion of sodium nitrite, and to study the pharmacokinetics of nitrite, during a 14 day infusion in patients with ruptured cerebral aneurysms.
- Trial name
- NCT00873015
- Testing
- Sodium nitrite, Saline
- Where
- United States
- Volunteers
- 19 people
- Sponsor
- Hope Pharmaceuticals
Vasospasm, Intracranial, Subarachnoid Hemorrhage
An Evaluation of Non-invasive Acoustic Approach to Detect and Monitor Cerebral Vasospasm
HeadSense (HS)-1000 device, a proprietary non-invasive brain monitor, is expected to safely and accurately monitor physiological signs of the brain with minimal discomfort to patients, providing information about normal or…
- Trial name
- NCT02704637
- Testing
- HS-1000
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- HeadSense Medical
Aneurysmal Subarachnoid Hemorrhage
Clazosentan in Reducing Vasospasm-related Morbidity and All-cause Mortality in Adult Patients With Aneurysmal Subarachnoid Hemorrhage Treated by Surgical Clipping
The aim of this study is to demonstrate that clazosentan, administered as a continuous intravenous infusion at 5 mg/h until Day 14 post aneurysmal subarachnoid hemorrhage (aSAH), reduces the incidence of cerebral vasospasm…
- Trial name
- CONSCIOUS-2 (NCT00558311)
- Testing
- Clazosentan
- Where
- 117 sites in United States, Australia and 27 more
- Volunteers
- 1,157 people
- Sponsor
- Idorsia Pharmaceuticals Ltd.
Aneurysmal Subarachnoid Hemorrhage, Cerebral Vasospasm
Safety Study of Carotid Body Neurostimulation to Treat Cerebral Vasospasm
The purpose of this study is to evaluate the safety and performance of the Delta system in the treatment of cerebral vasospasm post aneurysmal subarachnoid hemorrhage (aSAH) patients.
- Trial name
- NCT02129413
- Testing
- Delta system
- Where
- 7 sites in Czechia, Germany and 1 more
- Volunteers
- 23 people
- Sponsor
- Samson NeuroSciences
Vasospasm, Intracranial, Subarachnoid Hemorrhage
Lumenate Observational Vasospasm Interventional Trial (LOVIT)
The LOVIT study is a European prospective, multi-center, open-label, single-arm feasibility trial designed to determine the safety and angiographic effectiveness through 30 days post treatment with Lumenate Intraluminal Device in…
- Trial name
- LOVIT (NCT03511040)
- Testing
- Lumenate Intraluminal Device
- Where
- 5 sites in France, Germany and 2 more
- Volunteers
- 20 people
- Sponsor
- Neurvana Medical
Aneurysmal Subarachnoid Hemorrhage
Clazosentan in Aneurysmal Subarachnoid Hemorrhage
The aim of this study is to demonstrate that clazosentan, administered as a continuous intravenous infusion at either 5 mg/h or 15 mg/h until Day 14 post aneurysmal subarachnoid hemorrhage (aSAH), reduces the incidence of…
- Trial name
- CONSCIOUS-3 (NCT00940095)
- Testing
- Clazosentan 5 m/h, Clazosentan 15 mg/h
- Where
- 145 sites in United States, Argentina and 26 more
- Volunteers
- 577 people
- Sponsor
- Idorsia Pharmaceuticals Ltd.
Aneurysmal Subarachnoid Hemorrhage
Clazosentan in Preventing the Occurrence of Cerebral Vasospasm Following an Aneurysmal Subarachnoid Hemorrhage (aSAH)
The purpose of the study is to measure how effective and safe three different doses of the drug clazosentan are in preventing vasospasm after subarachnoid hemorrhage.
- Trial name
- CONSCIOUS-1 (NCT00111085)
- Testing
- Clazosentan 1 mg/h, Clazosentan 5 mg/h, Clazosentan 15 mg/h
- Where
- 16 sites in United States, Canada
- Volunteers
- 413 people
- Sponsor
- Idorsia Pharmaceuticals Ltd.
Subarachnoid Hemorrhage
Intravenous Nitrite Infusion for Reversal of Cerebral Vasospasm After Subarachnoid Hemorrhage
The hypothesis is that intravenous infusion of sodium nitrite is safe and effective for the reversal of cerebral vasospasm after subarachnoid hemorrhage in patients with a cerebral aneurysm.
- Trial name
- NCT02176837
- Testing
- Sodium Nitrite
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- Hope Pharmaceuticals